Related Experiment Video
Updated: May 30, 2026
08:22
In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model
Published on: October 27, 2020
Myocardial protection in heart surgery
1Department of Cardiothoracic Surgery and Physiology, WSU Cardiovascular Research Institute, Wayne State University School of Medicine, Detroit, MI, USA. rmentzer@med.wayne.edu
Journal of Cardiovascular Pharmacology and Therapeutics
|August 9, 2011
Summary
Preventing heart muscle damage after surgery remains a challenge. Current strategies fail due to study limitations, hindering effective cardioprotection development for patients undergoing cardiac procedures.
Area of Science:
- Cardiology
- Cardiac Surgery
- Ischemia-Reperfusion Injury
Background:
- Myocardial stunning and necrosis post-cardiac surgery are significant unmet clinical needs.
- Myocardial stunning requires inotropic support, increasing mortality in high-risk patients.
- Myocardial infarction (MI) consequences are subtle but serious, with no effective prevention methods.
Purpose of the Study:
- Define the clinical problem of myocardial stunning and necrosis.
- Summarize outcomes of Phase II and III clinical trials for prevention.
- Identify research gaps to develop effective cardioprotective interventions.
Main Methods:
- Review of clinical trials focusing on myocardial stunning and necrosis prevention.
- Analysis of factors contributing to the failure of therapeutic interventions.
- Evaluation of endogenous cardioprotection mechanisms.
Main Results:
- Despite understanding molecular mechanisms, effective clinical prevention strategies are lacking.
- Clinical trial failures attributed to preclinical study limitations and surrogate markers.
- Lack of industry enthusiasm for developing new cardioprotective drugs.
Conclusions:
- Effective clinical interventions for myocardial stunning and necrosis are needed.
- Overcoming research and development hurdles is crucial for advancing cardioprotection.
- Addressing the gap between preclinical findings and clinical application is essential.
Related Concept Videos
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...